ABPI Logo
  • What we do
    • Working with Government and Parliament
    • Working with the NHS
    • Working with Industry and academia
    • Working with charities and patient organisations
    • Supporting medicines and vaccines development
    • How medicines are priced in the UK
    • Global campaigns
    FEATURED
    Brexit

    The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues. Click here for our view and for more information about how our sector is preparing for Brexit if there's 'no deal'.

    FEATURED
    Devolved Nations How medicines are priced in the UK

    Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. Find out how pharmaceutical companies are pioneering R&D into the next generation of treatments. 

  • Ethics
    • Disclosure UK
    • Clinical trial transparency
    • Research using animals
    FEATURED
    Disclosure UK

    The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines. 

    FEATURED
    Hospital Clinical trial transparency

    Clinical trials are the cornerstone of the research and development process and it is through trials that pharmaceutical companies are able to demonstrate the safety and efficacy of new medicines.

  • Facts and Figures
    • UK pharmaceutical market
    • Global pharmaceutical market
    • Science and innovation
    • Industry and academia
    FEATURED
    Science and innovation

    Medicines and vaccines have helped deliver incredible improvements in patient health. This section looks at expenditure on R&D in the UK and around the world.

    FEATURED
    Industry and academia

    The UK is a world leader in medical research and innovation, built on the foundation of collaborations between industry and academia throughout Britain.

  • Membership and events
    • Events
    • Working with our members​
    • ABPI Members List
    • Membership FAQs
    • Full membership
    • General Affiliate membership
    • Research Affiliate membership
    FEATURED
    Events

    Discover events for both members and non-members as well as speaking engagements of senior ABPI leadership.

     

    FEATURED
    Working with our members Working with our members​

    As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.

  • Who We Are
  • Media
  • Publications
  • Careers
  • Contact Us
MY ABPI LOGIN
  • The Association of the British Pharmaceutical Industry
  • What we do
  • Supporting medicines and vaccines development
  • Migraine

Migraine

CGRP inhibitors will offer a new opportunity for migraine sufferers, lowering the number and severity of migraine attacks. We won’t rest until migraine suffers can find relief.

New treatments using CGRP inhibitors offer new hope to migraine patients by giving them a chance to regain function and improve their quality of life.

What is the potential breakthrough for people living with migraines?

Migraine is one of the most common neurological conditions in the world, and 20% of patients suffer more than 15 migraine days per month. Current therapies are not very effective, leading to refractory patients who have no treatment option available. CGRP inhibitors work to block a key signalling process known to be involved in migraine mediation, to attenuate or prevent episodic or chronic migraine. This represents a new treatment paradigm, offering migraine patients a chance to regain function and improve their quality of life.

How will it help patients?

Patients currently suffer a estimated total of 3.9bn migraine days per year. Current therapies can struggle to sufficiently control migraine symptoms, especially if taken too late. CGRP inhibitors offer a new hope for patients who have no other treatments available, enabling patients to have more function during attacks, providing them with greater autonomy. Acute therapies have been shown to prevent some of the worst migraine symptom in 37% of patients.

How many patients could it help?

Migraine is one of the most common neurological conditions in the world, affecting about 10% of the general population in Europe. However, up to 50% of sufferers do not seek medical help due to lack of efficacy of existing treatments. CGRP inhibitors may provide a new treatment option, not only for patients taking existing medications, but also for those who opt out of treatment altogether. Thus, an extra 7 million EU patients – who would otherwise not seek out migraine therapy – could find much-needed relief.

Who could benefit most from these new treatments?

Women are 3 times more likely to suffer from migraine than men, meaning the impact of CGRP inhibitors is more likely to be felt by women. However, children and teenagers can also experience migraine, especially once puberty is reached, resulting in loss of time from school. Extended school absences can have longer term consequences on a pupil’s education, which can have a wider impact on productivity later in life.

What is the potential impact on Europe’s healthcare systems?

Higher efficacy therapies can lower the number of primary care appointments needed for existing patients, as well as potentially lowering the burden of medication overuse headache. These new therapies can improve productivity, through lowering the number of days lost to work and school, thereby enabling patients to live fuller lives.

 

Supporting medicines and vaccines development

  • Vaccines
  • Alzheimer’s disease
  • Bacterial infections
  • Blood cancers
  • Diabetes
  • Haemophilia
  • Lung cancer
  • Microbe therapy
  • Migraine
  • NASH (Non-Alcoholic Steatohepatitis)
  • ABPI LINC

RELATED LINKS

  • We Won't Rest

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2019

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Careers
  • Disclosure UK
  • Job Opportunities
  • Schools

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy
  • Privacy Policy
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.